Global pharmaceutical company, Allergan, intends to acquire Tobira Therapeutics, a clinical-stage bio-pharma company, for an approximate consideration of $1.695bn.

The companies have signed a definitive agreement, according to which Allergan’s subsidiary will initiate a cash tender offer to purchase all of the outstanding shares of Tobira common stock for $28.35 a share and up to $49.84 a share in contingent value rights (CVRs).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The consideration is payable based on the achievement of certain developments, regulatory and commercial milestones.

“CA Casyso is a leading developer of IVD testing equipment for patient blood management (PBM) and is reputed for its flagship ROTEM testing systems.”

The acquisition is expected to further strengthen Allergan’s Gastroenterology research and development (R&D) pipeline with Cenicriviroc (CVC) and Evogliptin, two complementary development programmes for the treatment of non-alcoholic steatohepatitis (NASH).

In a move to expand and strengthen its expertise in haemostasis and in-vitro diagnostics (IVD), IVD instruments developer, Instrumentation Laboratory (IL) has completed the acquisition of CA Casyso and its Tem subsidiaries including Tem Innovations GmbH, Tem International GmbH and Tem Systems.

CA Casyso is a leading developer of IVD testing equipment for patient blood management (PBM) and is reputed for its flagship ROTEM testing systems.

ROTEM blood analysers provide a rapid diagnosis of coagulopathies, a bleeding disorder, and allow treatment with targeted therapy to reduce the risk of massive bleeding and haemorrhagic shock.

In a $4.325bn cash deal, pharmaceutical company Johnson & Johnson (J&J) has agreed to purchase Abbott Medical Optics (AMO), the eye-surgery equipment division of Abbott Laboratories.

The acquisition, which is expected to close by April 2017, will complement J&J’s existing portfolio of contact lenses and solutions by adding more products.